ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-08	US$0.000001	-99.00%	1,750
26-07-06	US$0.000100	0.00%	8,197
26-07-02	US$0.000100	0.00%	30,000
26-06-30	US$0.000100	0.00%	12,099

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 14:29:46 2026-07-08 EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-99.00%	-99.00%

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.6M 3.32M 3.07M 5.82M 393M 5.93M 39.92M 15.51M 192M 15.4M 15.06M 667M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.14M -1.05M -970K -1.84M -124M -1.87M -12.61M -4.9M -60.72M -4.87M -4.76M -211M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
23-04-11	Insider Buy: Obseva	MT
23-04-05	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
23-03-31	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
23-03-22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
23-03-15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
23-03-13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
23-03-13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
23-03-13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
23-03-13	ObsEva SA Announces Executive Changes	CI
23-03-03	Top Premarket Gainers	MT

22-08-30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
22-08-01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
22-07-29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
22-06-03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
22-04-26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-03-31	ObsEva Files Year End 2022 Financial Statements	GL
23-03-22	OBSEVA SA : Other Events (form 8-K)	AQ
23-03-15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

23-04-20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
23-04-06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
23-04-06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
23-03-31	Obseva bleibt 2022 tief in den roten Zahlen
23-03-31	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.58
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-04-05	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-27	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-22	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-99.00%	-99.00%	-	-	11.72K
ARGENX SE	-1.53%	+0.78%	+72.33%	+129.70%	57.72B
WUXI APPTEC CO., LTD.	-2.45%	-7.83%	+63.92%	+83.15%	52.65B
INSMED INCORPORATED	+3.27%	+8.91%	+21.21%	+486.76%	24.46B
BIONTECH SE	-0.81%	-0.42%	-16.24%	-12.47%	23.84B
WUXI BIOLOGICS (CAYMAN) INC.	+4.09%	+3.63%	+43.47%	-2.21%	19.28B
GENMAB A/S	-0.24%	+5.11%	+38.76%	-26.41%	17.8B
PHARMAESSENTIA CORPORATION	+2.34%	+12.50%	+224.02%	+380.99%	17.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.29%	+2.18%	+36.59%	-	15.28B
EXELIXIS, INC.	-1.70%	+3.98%	+28.96%	+190.57%	14.35B
Average	-9.62%	-4.94%	+57.00%	+153.76%	24.27B
Weighted average by Cap.	-0.28%	+3.12%	+57.89%	+141.95%

	2021	2022
Net sales	-	19.64M 17.22M 15.9M 14.69M 27.85M 1.88B 28.41M 191M 74.27M 920M 73.74M 72.13M 3.19B
Net income	-58.38M -51.2M -47.27M -43.68M -82.8M -5.59B -84.45M -568M -221M -2.74B -219M -214M -9.5B	-29.88M -26.21M -24.19M -22.36M -42.38M -2.86B -43.23M -291M -113M -1.4B -112M -110M -4.86B
Net Debt	-28.08M -24.62M -22.73M -21.01M -39.82M -2.69B -40.62M -273M -106M -1.32B -105M -103M -4.57B	-5.4M -4.73M -4.37M -4.04M -7.65M -517M -7.81M -52.54M -20.41M -253M -20.27M -19.82M -878M